Inactive Instrument

Kolinpharma S.p.A.

KIP

IT0005322950

Kolinpharma increases turnover in the first half of the year

July 28, 2023 at 02:02 pm EDT

(Alliance News) - Kolinpharma's board of directors on Friday reviewed preliminary turnover as of June 30, which amounted to about EUR6.7 million, an increase of about 17 percent from EUR5.7 million in the first half of 2022.

Rita Paola Petrelli, -president of the company- commented, "We close the first half of 2023 with a preliminary turnover figure that stands at EUR6.7 million, with a double digit growth of about 17 percent compared to the first half of 2022."

"In terms of KPIs on medical prescriptions, the second quarter is also positive with a number of 213,309 units, up 7.5 percent in terms of volume and 6.6 percent in terms of value. Development activities continue on both the R&D and commercial fronts in Italy and abroad. 2023 is a special year for the Kolinpharma project, 10 years since its establishment, an ambitious project has become a splendid reality."

Kolinpharma closed Friday's session in the green by 2.6 percent at EUR9.90 per share

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Go to the original article.
Legal disclaimer

Latest news about Kolinpharma S.p.A.

Kolinpharma presents supplement; patent application already filed	23-08-30	AN
Kolinpharma increases turnover in the first half of the year	23-07-28	AN
Igea Holding raises offer to take over Kolinpharma shares	23-07-28	AN
Kolinpharma suspends buyback plan after takeover bid by Igea Holding	23-06-28	AN
Kolinpharma S.p.A.'s Equity Buyback announced on May 15, 2023, has suspended.	23-06-27	CI
Kolinpharma continues with share buyback	23-06-22	AN
Kolinpharma S.p.A. commences an Equity Buyback Plan under the authorization approved on April 21, 2023.	23-05-14	CI
Kolinpharma, over 200,000 medical prescriptions in first quarter	23-05-04	AN
Kolinpharma, shareholders' meeting confirms board of directors	23-04-21	AN
Kolinpharma S.p.A.'s Equity Buyback announced on April 28, 2022, has expired.	23-04-20	CI
Europeans up; Tenaris at bottom on Mib.	23-04-14	AN
Kolinpharma, profit halves in 2022 but revenue rises	23-03-22	AN
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
Kolinpharma, prescriptions and whistleblowers grow in fourth quarter	23-02-07	AN
Kolinpharma goes ahead with buybacks of its own common stock	23-01-17	AN
Kolinpharma goes ahead with share buybacks	23-01-11	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	23-01-10	AN
Kolinpharma purchased its own shares for EUR22,000 approx.	23-01-10	AN
Kolinpharma purchased its own shares for about EUR19,000	22-12-28	AN
Kolinpharma S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Kolinpharma S.p.A.'s Equity Buyback announced on February 25, 2022, has expired.	22-04-27	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 28, 2022.	22-04-27	CI
Kolinpharma S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Kolinpharma S.p.A. commences an Equity Buyback Plan, under the authorization approved on April 29, 2021.	22-02-25	CI
Kolinpharma S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-27	CI

Chart Kolinpharma S.p.A.

Duration

Period

More charts

Company Profile

Kolinpharma SpA is an Italy-based company specialized in the pharmaceutical industry. The Company offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+34.00%	664B
NOVO NORDISK A/S	+29.29%	567B
JOHNSON & JOHNSON	-7.75%	354B
MERCK & CO., INC.	+18.53%	330B
ABBVIE INC.	+4.95%	286B
ASTRAZENECA PLC	+13.79%	234B
NOVARTIS AG	+4.93%	199B
ROCHE HOLDING AG	-9.78%	196B
AMGEN INC.	-4.89%	148B

Other Pharmaceuticals